| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 13, 2013
Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - June 13, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo...
-
Jun 5, 2013
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - June 5, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 34th Annual...
-
Jun 4, 2013
Thomson Reuters ONE via COMTEX) --Pacific Plus PTA Catheter Allows for Treatment of Myriad Arteries, from Renal and Iliac to Femoral and Popliteal MINNEAPOLIS -- June 4, 2013 -- Expanding its...
-
Jun 3, 2013
Thomson Reuters ONE via COMTEX) --Company Plans to Submit First Module of U.S. Approval Application for Novel Peripheral Angioplasty Device to FDA Over Summer MINNEAPOLIS -- June 3, 2013 --...
-
May 31, 2013
Thomson Reuters ONE via COMTEX) --Three-Year Clinical Data Presented at Annual Meeting of Society for Vascular Surgery Reaffirms Physician Confidence in Market-Leading Endovascular Device SAN...
-
May 30, 2013
(Thomson Reuters ONE via COMTEX) --Global Market-Leader in Medical Technology for Endovascular Aortic Repair Also Receives 510(k) Clearance for Sentrant Introducer Sheath MINNEAPOLIS -- May 30,...
-
May 24, 2013
Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - May 24, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Sanford...
-
May 23, 2013Presented at EuroPCR, One-Year Data from BELLO Study Show Durability of Clinical Results Following Treatment of De Novo Lesions with Novel Angioplasty Device
PARIS -- May 23, 2013 -- One-year data from an Italian multicenter randomized controlled trial of the IN.PACT Falcon drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) demonstrate positive and...
-
May 23, 2013Replacing Degenerated Surgical Valves with CoreValve Results in Significant Hemodynamic Improvements for Patients
MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received Conformité Européenne (CE) Mark for valve-in-valve (VIV) procedures using the CoreValve® and CoreValve®...
-
May 23, 2013Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S.
MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal...